Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Violation of price...

    Violation of price capping of Coronary stent to attract NPPA action; Minister

    Farhat NasimWritten by Farhat Nasim Published On 2020-02-22T16:42:22+05:30  |  Updated On 22 Feb 2020 4:42 PM IST
    Violation of price capping of Coronary stent to attract NPPA action; Minister

    "Institutions such as hospitals/nursing homes/clinics utilizing Coronary Stents for Angioplasty are bound to abide by the ceiling prices fixed by the Government for Coronary Stents. If any violation of price capping regarding Coronary Stents is noticed by NPPA, then overcharging proceedings is initiated against such hospital/manufacturer concerned for recovery of the overcharged amount."

    New Delhi: The Minister in the Ministry of Chemical and Fertilizers recently informed the Parliament that if any violation of price capping regarding Coronary Stents is noticed by the National Pharmaceutical Pricing Authority (NPPA), then overcharging proceedings is initiated against such hospital/manufacturer concerned for recovery of the overcharged amount.

    This came while responding to a query raised by Dr Banda Prakash during a recent Rajya Sabha session. He asked whether the margin of profit has been added on MRP fixed for different types of coronary stents by NPPA and its details. He further questioned about the action that could be taken against hospitals in case they demand a higher price than MRP for stents.

    Responding to the query, the Minister stated that NPPA in February 2017 fixed ceiling prices for Coronary Stents namely (i) Bare Metal Stents (BMS) and (ii) Drug-Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents considering methodology of Price to Distributors (PTD) plus 8% Margin for arriving at ceiling prices for the same. The ceiling prices for Coronary Stents were revisited and revised vide Order dated 12th February 2018 after considering the methodology of Landed Cost plus 50% margin for BMS and Landed Cost plus 35% margin for DES. The ceiling prices so fixed vide the aforesaid Orders is inclusive of Trade Margin of 8%.

    Also Read: NPPA Revises Price Of Coronary Stents; Check Out Details

    The ceiling prices fixed vide aforesaid order has been revised several times considering the increase in Wholesale Price Indexes. He further mentioned a table indicating the price revision of Coronary Stents as;

    Particulars Drug-Eluting Stents (Rs.) Bare Metal Stents (Rs.) Remarks

    Ceiling prices fixed on 13-02-2017 under Para 19 of the Drugs (Prices Control) Order, 2013 (DPCO, 2013) 29,600 7,260 Initial fixations of ceiling prices with 8% Margin

    Ceiling prices w.e.f. 01-4-2017 30,180 7,400 WPI increase @ 1.97186%

    Ceiling prices re-fixed on 12-02-2018 under Para 19 of the DPCO, 2013 27,890 7,660 Ceiling prices revisited based on Landed Cost

    Ceiling prices w.e.f. 01-4-2018 28,849 7,923 WPI increase @ 3.43812%

    Ceiling prices w.e.f. 01-4-2019 30,080 8,261 WPI increase @ 4.2662%.

    Clarifying about the regulatory actions in case of violation of the ceiling price of the Coronary Stents fixed by NPPA, the minister said;

    "Institutions such as hospitals/nursing homes/clinics utilizing Coronary Stents for Angioplasty are bound to abide by the ceiling prices fixed by the Government for Coronary Stents. If any violation of price capping regarding Coronary Stents is noticed by NPPA, then overcharging proceedings is initiated against such hospital/manufacturer concerned for recovery of the overcharged amount."

    Also Read: With Questions About Safety Of Meril's Made In India BVS Stent, NPPA Defers Its Appeal For Price Exemption

    nppadrug eluting stentcoronary stentstent price

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok